Coagulation Factors

May 2025 Quick Question Summary

Our May 2025 Quick Question was meant to be a brain teaser inspired by Dave McGlasson’s December 2023 Clot Club entry, “Do We Need to Standardize Coagulation Nomenclature in Today’s Laboratory Environment?” The question listed several assays that use the letter C. “Which is the routine assay for inflammation?” It seems that only four of […]

Quick Question Archive

Plasma Collection for IVD

Thanks to Mr. Darcy Shannon of Drumlin Plasma, Inc. for the attached SOP, which distinguishes between plasma collected for IVD applications, such as coagulation calibrators, controls, and reagents, and plasma collected to produce therapeutic plasma fractions.

Bleeding Disorders

February 2025 Quick Question

Our February 2025 Quick Question is a quiz that asks “What factor deficiency is associated with poor wound healing?” You may answer on the right and if convenient, add your comments below and watch for the results on or after March 1.

Hot Topics in Hemostasis: Nomenclature Standardization

Frequent contributor David L. McGlasson is featured in the Differential Discussions series hosted by Assistant Professor David Cabral, MBA, MLS(ASCP)cm, SH(ASCP)cm of the University of Massachusetts Dartmouth, and Assistant Professor Malissa Norfolk, MBA, MLS(ASCP)cm, SH(ASCP)cm, of the University of Maine-Augusta faculty. Click here to meet Malissa and David, and to hear Mr. McGlasson’s discussion of […]

Coagulation Factors

March 2024 Quick Question Summary: Factor Deficiency

Our March 2024 Quick Question was a quiz. The question was, “What factor deficiency causes bleeding but doesn’t prolong the PT or PTT?” Our 75 respondents answered as follows: FVIII: 7 [9%] FIX: 3 [4%] FXI: 3 [4%] FXII: 8 [11%] FXIII: 54 [72%] Factor VIII, IX, XI, and XII deficiencies prolong the PTT but […]

Bleeding Disorders

Feb 2024 Quick Question: Rosenthal Syndrome

Our February 2024 Quick Question is a quiz that tests the knowledge we gained in our entry-level coagulation courses. At the end of February, we’ll use this as a means to discuss the efficacy of currently available DOACs and some new developments.

Coagulation Factors

WFH Statement on Cryoprecipitate

The World Federation of Hemophilia [WFH] is deeply concerned by the inclusion of pathogen-reduced and non-pathogen-reduced cryoprecipitate in the World Health Organization’s 23rd Essential Medicines List [EML] and Essential Medicines List for Children [EMLC]. Click here for the 12-23-23 WFH statement.

Bleeding Disorders

Coag Factor Nomenclature

In a follow-up to our September 8, 2023 Arabic Numerals discussion, refer to Dave McGlasson’s Clot Club entry “Do We Need to Standardize Coagulation Nomenclature?” Dave includes a comprehensive review of procoagulant functions, names, and properties.

Coagulation Factors

Acquired Hemophilia, rpVIII, and Bethesda Titer

Here is a 12-2-23 email from Hrvoje Melinšćak MD, Consultant in Haematology, the Warren Alpert Medical School of Brown University, Rhode Island Hospital/The Miriam Hospital. I would enquire regarding rpFVIII’s impact on inhibitor titre assessment through the Bethesda assay in a case regarding acquired haemophilia A. Does significant background rpFVIII (Obizur) concentrate lend to significant […]

Bleeding Disorders

FXII and Inflammation

This question was posted in the Rutgers graduate course, CLSC 5124 Advanced Hemostasis: Explain how FXII and FXI are activated by vascular assist devices and show their connection with inflammation. Here is an answer provided by one of the course participants: The contact pathway may be initiated by FXII binding to a negatively charged surface […]

Arterial Thrombosis

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question